Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Advanced-Stage Hodgkin Lymphoma in the East of England Cancer Network: A 10-Year Comparative Analysis of Outcomes for Patients Treated with ABVD or Escalated BEACOPP in the Non-Trial Setting Compared with Age-Matched Patients Treated in the Multinational RATHL Trial

James Russell, MD, Angela Collins, MD, Alexis Fowler, MD, Mamatha Karanth, MD, Isabel Lentell, MD, Chandan Saha, MD, Suzanne Docherty, MD, Joseph Padayatty, MD, Kyaw Maw, MD, Lisa Cooke, MD, Andrew Hodson, MD, Nimish Shah, MD, Shalal Sadullah, MD, Nicholas Grigoropoulos, MD PhD, Wendi Qian, Amy A Kirkwood, Benjamin J Uttenthal, MD PhD, Peter Johnson, MD FRCP, George A Follows, MD PhD

Blood (2017) 130 (Supplement 1): 735.

https://doi.org/10.1182/blood.V130.Suppl_1.735.735

Published: 2017

Journal Articles

Outcome of Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: Subgroup Analysis from the UK NCRI R-CHOP 14 Vs 21 Trial

Blood (2015) 126 (23): 1516.

https://doi.org/10.1182/blood.V126.23.1516.1516

Published: 2015

Journal Articles

Risk of CNS Relapse with Diffuse Large B-Cell Lymphoma (DLBCL) in the Rituximab Era: Results from the UK NCRI R-CHOP 14 v 21 Trial

Mary Gleeson, FRCPath, David Cunningham, FMedSci, Eliza A Hawkes, MD, Wendi Qian, PhD, Paul Smith, MSc, Nick Chadwick, Paul Mouncey, MSc, Andrew Jack, PhD, Christopher Pocock, MD PhD, Kirit M Ardeshna, MD FRCPath, John Radford, Andrew McMillan, PhD, John Davies, FRCPE, Deborah Turner, FRCPath, Anton Kruger, FRCPath, Peter W.M. Johnson, FRCP, Joanna Gambell, BSc, David C Linch, FMedSci

Blood (2014) 124 (21): 1723.

https://doi.org/10.1182/blood.V124.21.1723.1723

Published: 2014

Journal Articles

Prognostic Effect Of More Than 1 Extranodal Site Of Disease For Patients With Diffuse Large B Cell Lymphoma (DLBCL) In The Rituximab Era: Results From The UK NCRI R-CHOP 14 Versus 21 Trial

Mary Gleeson, FRCPath, Wendi Qian, PhD, David Cunningham, FMedSci, Eliza Hawkes, FRACP, Andrew Jack, PhD, Paul Smith, MSc, Paul Mouncey, MSc, Christopher Pocock, PhD, Kirit M Ardeshna, FRCPath, John Radford, MD, Andrew McMillan, FRCPath, John Davies, FRCPE, Deborah Turner, FRCPath, Anton Kruger, FRCPath, Peter Johnson, FRCP, Joanna Gambell, BSc, David Linch, FMedSci

Blood (2013) 122 (21): 4268.

https://doi.org/10.1182/blood.V122.21.4268.4268

Published: 2013

Journal Articles

A Phase 1 Trial of Escalating High Dose Methotrexate Supported by Glucarpidase to Treat Patients with Primary Central Nervous System Lymphoma (PCNSL). (CRUK/08/010)

Roderick J. Johnson, MD, Andrew Davies, MD, Siow-Ming Lee, MD, Dianne Gilson, MD, Paul Smith, PhD, Wendi Qian, Nivette Braganca, Nadjet El-mehidi, Peter Johnson

Blood (2012) 120 (21): 4850.

https://doi.org/10.1182/blood.V120.21.4850.4850

Published: 2012

Journal Articles

An Intergroup Randomised Trial of Rituximab Versus a Watch and Wait Strategy In Patients with Stage II, III, IV, Asymptomatic, Non-Bulky Follicular Lymphoma (Grades 1, 2 and 3a). A Preliminary Analysis

Kirit M Ardeshna, MD, Wendi Qian, Paul Smith, June Warden, Lindsay Stevens, Christopher FE Pocock, MD, PhD, Fiona Miall, MD, David Cunningham, MD, John Davies, MD, Jan Walewski, A. Burhan Ferhanoglu, MD, Ken Bradstock, MB, PhD, David C Linch, MD, FMedSci

Blood (2010) 116 (21): 6.

https://doi.org/10.1182/blood.V116.21.6.6

Published: 2010

Journal Articles

Response: Bone marrow involvement and outcome in Burkitt lymphoma and diffuse large B-cell lymphoma

Andrew S. Jack, Sharon L. Barrans, Wendi Qian, Sally P. Stenning, Graham M. Mead

Blood (2009) 114 (2): 486–487.

https://doi.org/10.1182/blood-2009-04-214627

Published: 2009

Journal Articles

Quality Control of PET Imaging in a Multicentre Phase III Trial (RAPID) Involving Randomisation of Patients with Stages IA and IIA Hodgkin Lymphoma Who Are PET ‘negative’ after 3 Cycles of ABVD Chemotherapy.

Sally F Barrington, Michael J O’Doherty, Jane MacKewn, Paul Schleyer, Wendi Qian, Philippa Patrick, Timothy Illidge, Ruth Pettengell, Peter Hoskin, Barry Hancock, John Radford

Blood (2008) 112 (11): 1449.

https://doi.org/10.1182/blood.V112.11.1449.1449

Published: 2008

Journal Articles

Randomised Comparison of the Stanford V (SV) Regimen and ABVD in the Treatment of Advanced Hodgkin Lymphoma (HL): Results from a UK NCRI Lymphoma Group Study, ISRCTN 64141244

Peter W.M. Johnson, MD, FRCP, Alan Horwich, PhD, FRCR, MRCP, Andrew Jack, MD, FRCPath, Graham Mead, DM, FRCP, Barry Hancock, MD, FRCP, Paul Smith, Wendi Qian, Philippa Patrick, PhD, Andrew Pettitt, David Cunningham, Peter Hoskin, MD, FRCR

Blood (2008) 112 (11): 370.

https://doi.org/10.1182/blood.V112.11.370.370

Published: 2008

Journal Articles

Results of the 2nd Planned Interim Analysis of the RAPID Trial (involved field radiotherapy versus no further treatment) in Patients with Clinical Stages 1A and 2A Hodgkin Lymphoma and a ‘negative’ FDG-PET Scan after 3 Cycles ABVD

John Radford, Michael O’Doherty, Sally Barrington, Wendi Qian, Philippa Patrick, Stewart Coltart, Dominic Culligan, Jennie Wimperis, Eric Bessell, David Linch, Peter Johnson, David Cunningham, T. Andrew Lister, Peter Hoskin, Ruth Pettengell, Barry Hancock, Timothy Illidge

Blood (2008) 112 (11): 369.

https://doi.org/10.1182/blood.V112.11.369.369

Published: 2008

Journal Articles

A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial)

Graham M. Mead, Sharon L. Barrans, Wendi Qian, Jan Walewski, John A. Radford, Max Wolf, Simon M. Clawson, Sally P. Stenning, Claire L. Yule, Andrew S. Jack

Blood (2008) 112 (6): 2248–2260.

https://doi.org/10.1182/blood-2008-03-145128

Published: 2008

Journal Articles

A Prospective, Randomised Trial of Chlorambucil, Mitoxantrone and Dexamethasone (CMD) Versus Fludarabine, Mitoxantrone and Dexamethasone (FMD) for Advanced Follicular Lymphoma (Real Grades I-III, Stages III/IV).

Andrew Haynes, MD, FRCP, Andrew McMillan, MB, FRCP, Andrew Jack, MD, FRCPath, Wendi Qian, BSc, Ira Jakupovic, BSc, Paul Smith, BSc, Archie Prentice, MB, FRCP

Blood (2006) 108 (11): 534.

https://doi.org/10.1182/blood.V108.11.534.534

Published: 2006

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Advanced-Stage Hodgkin Lymphoma in the East of England Cancer Network: A 10-Year Comparative Analysis of Outcomes for Patients Treated with ABVD or Escalated BEACOPP in the Non-Trial Setting Compared with Age-Matched Patients Treated in the Multinational RATHL Trial

Outcome of Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: Subgroup Analysis from the UK NCRI R-CHOP 14 Vs 21 Trial

Risk of CNS Relapse with Diffuse Large B-Cell Lymphoma (DLBCL) in the Rituximab Era: Results from the UK NCRI R-CHOP 14 v 21 Trial

Prognostic Effect Of More Than 1 Extranodal Site Of Disease For Patients With Diffuse Large B Cell Lymphoma (DLBCL) In The Rituximab Era: Results From The UK NCRI R-CHOP 14 Versus 21 Trial

A Phase 1 Trial of Escalating High Dose Methotrexate Supported by Glucarpidase to Treat Patients with Primary Central Nervous System Lymphoma (PCNSL). (CRUK/08/010)

An Intergroup Randomised Trial of Rituximab Versus a Watch and Wait Strategy In Patients with Stage II, III, IV, Asymptomatic, Non-Bulky Follicular Lymphoma (Grades 1, 2 and 3a). A Preliminary Analysis

Response: Bone marrow involvement and outcome in Burkitt lymphoma and diffuse large B-cell lymphoma

Quality Control of PET Imaging in a Multicentre Phase III Trial (RAPID) Involving Randomisation of Patients with Stages IA and IIA Hodgkin Lymphoma Who Are PET ‘negative’ after 3 Cycles of ABVD Chemotherapy.

Randomised Comparison of the Stanford V (SV) Regimen and ABVD in the Treatment of Advanced Hodgkin Lymphoma (HL): Results from a UK NCRI Lymphoma Group Study, ISRCTN 64141244

Results of the 2nd Planned Interim Analysis of the RAPID Trial (involved field radiotherapy versus no further treatment) in Patients with Clinical Stages 1A and 2A Hodgkin Lymphoma and a ‘negative’ FDG-PET Scan after 3 Cycles ABVD

A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial)

A Prospective, Randomised Trial of Chlorambucil, Mitoxantrone and Dexamethasone (CMD) Versus Fludarabine, Mitoxantrone and Dexamethasone (FMD) for Advanced Follicular Lymphoma (Real Grades I-III, Stages III/IV).

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only